Juvaris Series A Grows

Juvaris BioTherapeutics Inc., a Pleasanton, Calif.-based developer of vaccines for cancer and infectious diseases, has closed its Series A round with around $15.88 million according to a regulatory filing. The company announced the deal earlier in the year, saying it would be worth $12 million split between two tranches. The filing indicates that just over $13.8 million came in the form of equity, while the remainder was debt and a few convertible notes. Kleiner Perkins Caufield & Byers led the round. www.juvaris.com